@article{262a014cd8254fffbf87fec5d4e05b59,
title = "The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity",
abstract = "Missense mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of familial Parkinson{\textquoteright}s disease (PD); however, pathways regulating LRRK2 subcellular localization, function, and turnover are not fully defined. We performed quantitative mass spectrometry–based interactome studies to identify 48 novel LRRK2 interactors, including the microtubule-associated E3 ubiquitin ligase TRIM1 (tripartite motif family 1). TRIM1 recruits LRRK2 to the microtubule cytoskeleton for ubiquitination and proteasomal degradation by binding LRRK2911–919, a nine amino acid segment within a flexible interdomain region (LRRK2853–981), which we designate the “regulatory loop” (RL). Phosphorylation of LRRK2 Ser910/Ser935 within LRRK2 RL influences LRRK2{\textquoteright}s association with cytoplasmic 14-3-3 versus microtubule-bound TRIM1. Association with TRIM1 modulates LRRK2{\textquoteright}s interaction with Rab29 and prevents upregulation of LRRK2 kinase activity by Rab29 in an E3-ligase–dependent manner. Finally, TRIM1 rescues neurite outgrowth deficits caused by PD-driving mutant LRRK2 G2019S. Our data suggest that TRIM1 is a critical regulator of LRRK2, controlling its degradation, localization, binding partners, kinase activity, and cytotoxicity.",
author = "Stormo, {Adrienne E.D.} and Farbod Shavarebi and Molly Fitzgibbon and Earley, {Elizabeth M.} and Hannah Ahrendt and Lum, {Lotus S.} and Erik Verschueren and Swaney, {Danielle L.} and Gaia Skibinski and Abinaya Ravisankar and {van Haren}, Jeffrey and Davis, {Emily J.} and Johnson, {Jeffrey R.} and {Von Dollen}, John and Carson Balen and Jacob Porath and Claudia Crosio and Christian Mirescu and Ciro Iaccarino and Dauer, {William T.} and Nichols, {R. Jeremy} and Torsten Wittmann and Cox, {Timothy C.} and Steve Finkbeiner and Krogan, {Nevan J.} and Oakes, {Scott A.} and Annie Hiniker",
note = "Funding Information: This work was made possible with support from the UCSF Parnassus Flow Cytometry Core (RRID:SCR_018206) and DRC center grant NIG P30 DK063720, RF1 AG058476 (S. Finkbeiner), P01 AG054407 (S. Finkbeiner), R01 NS124848 (S. Finkbeiner), the Michael J Fox Foundation (S. Finkbeiner), the Taube Koret Center for Neurodegenerative disease (S. Finkbeiner), Laurel Endowment for Pediatric Craniofacial Research (T.C. Cox), the Stowers Family Endowed Chair for Dental & Mineralized Tissue Research (T.C. Cox), Michael J. Fox Foundation LRRK2 Challenge 2014 ID9550 (C. Iaccarino), Fondazione Banco di Sardegna grant number 2014.0489 (C. Iaccarino), Fondo di Ateneo per la ricerca 2020 (C. Iaccarino) and Fondo di Ateneo per la ricerca 2020 (C. Crosio), S10 RR026758 (T. Wittmann), National Institutes of Health R01EY027810 (S.A. Oakes), National Institutes of Health R01CA219815 (S.A. Oakes), National Institutes of Health K08NS090633 (A. Hiniker), DoD W81XWH-18-1-0376 (A. Hi-niker), and the American Federation for Aging Research (A. Hiniker). Funding Information: This work was made possible with support from the UCSF Parnassus Flow Cytometry Core (RRID:SCR_018206) and DRC center grant NIG P30 DK063720, RF1 AG058476 (S. Finkbeiner), P01 AG054407 (S. Finkbeiner), R01 NS124848 (S. Finkbeiner), the Michael J Fox Foundation (S. Finkbeiner), the Taube Koret Center for Neurodegenerative disease (S. Finkbeiner), Laurel Endowment for Pediatric Craniofacial Research (T.C. Cox), the Stowers Family Endowed Chair for Dental & Mineralized Tissue Research (T.C. Cox), Michael J. Fox Foundation LRRK2 Challenge 2014 ID9550 (C. Iaccarino), Fondazione Banco di Sardegna grant number 2014.0489 (C. Iaccarino), Fondo di Ateneo per la ricerca 2020 (C. Iaccarino) and Fondo di Ateneo per la ricerca 2020 (C. Crosio), S10 RR026758 (T. Wittmann), National Institutes of Health R01EY027810 (S.A. Oakes), National Institutes of Health R01CA219815 (S.A. Oakes), National Institutes of Health K08NS090633 (A. Hiniker), DoD W81XWH-18-1-0376 (A. Hiniker), and the American Federation for Aging Research (A. Hiniker). S. Finkbeiner is on the scientific advisory boards of Foresite Capital and Foresite Laboratories (San Francisco, CA), PurMinds Neuropharma (Toronto, ON), and Origami Therapeutics (San Diego, CA). S.A. Oakes is a founder, equity holder, and consultant for OptiKIRA, LLC (Cleveland, OH) and a consultant for Kezar Life Sciences (South San Francisco, CA). The authors declare no further competing financial interests. Publisher Copyright: {\textcopyright} 2022 Stormo et al. This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).",
year = "2022",
month = apr,
day = "4",
doi = "10.1083/jcb.202010065",
language = "English (US)",
volume = "221",
journal = "Journal of Cell Biology",
issn = "0021-9525",
publisher = "Rockefeller University Press",
number = "4",
}